Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR0891)
Drug Name
Isradipine
Synonyms
Isradipin; Isradipine (Dynacirc); Isradipine(Dynacirc); Isradipino; Isradipino [Spanish]; Isradipinum; Isradipinum [Latin]; Isrodipine; Clivoten; DynaCirc; DynaCire; DynaCire CR; Dynacirc CR; Dynacrine; Esradin; PN 200; PN 200-110; PN-200-110; Prescal; Rebriden; isradipine; (+-)-Isradipine; (+/-)-Isradipine; 3,5-Pyridinedicarboxylic acid, 4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester; 75695-93-1; Lomir; MFCD00153820
Indication Essential hypertension [ICD11: BA00] Approved [1]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 371.4 Topological Polar Surface Area 104
Heavy Atom Count 27 Rotatable Bond Count 6
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 8
Cross-matching ID
PubChem CID
3784
ChEBI ID
CHEBI:6073
CAS Number
75695-93-1
TTD Drug ID
D0HC8Q
Formula
C19H21N3O5
Canonical SMILES
CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC=CC3=NON=C32)C(=O)OC
InChI
1S/C19H21N3O5/c1-9(2)26-19(24)15-11(4)20-10(3)14(18(23)25-5)16(15)12-7-6-8-13-17(12)22-27-21-13/h6-9,16,20H,1-5H3
InChIKey
HMJIYCCIJYRONP-UHFFFAOYSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
Dehydro Isradipine DM001026
10406778
Unclear 1 [3] , [5]
Demethyl Isradipine DM001030
14519595
Unclear 1 [3] , [5]
Isradipine Lactone DM001029
46782005
Unclear 1 [3] , [5]
PN 204-144 DM001031
10336663
Unclear 1 [3] , [5]
Dehydro Isradipine Lactone DM001027
29976815
Unclear 2 [3] , [5]
PN 204-145 DM001028
10314337
Unclear 2 [3] , [5]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR001266 Isradipine Dehydro Isradipine Unclear Unclear [3], [5]
MR001267 Isradipine Isradipine Lactone Unclear Unclear [3], [5]
MR001268 Isradipine Demethyl Isradipine Unclear Unclear [3], [5]
MR001269 Isradipine PN 204-144 Unclear Unclear [3], [5]
MR001264 Dehydro Isradipine Dehydro Isradipine Lactone Unclear Unclear [3], [5]
MR001265 Dehydro Isradipine PN 204-145 Unclear Unclear [3], [5]
⏷ Show the Full List of 6 MR(s)
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 3A4 (CYP3A4) DME0001 Homo sapiens
CP3A4_HUMAN
1.14.14.55
[2]
Cytochrome P450 3A4 (CYP3A4) DME0001 Homo sapiens
CP3A4_HUMAN
1.14.14.55
[3]
Unclear metabolic mechanism (DME-unclear) DME1251 Bacteroides fragilis Not Available Not Available [4]
Unclear metabolic mechanism (DME-unclear) DME1254 Bacteroides thetaiotaomicron Not Available Not Available [4]
Unclear metabolic mechanism (DME-unclear) DME1385 Bacteroides xylanisolvens Not Available Not Available [4]
Unclear metabolic mechanism (DME-unclear) DME1393 Blautia hansenii Not Available Not Available [4]
Unclear metabolic mechanism (DME-unclear) DME1402 Clostridium botulinum Not Available Not Available [4]
Unclear metabolic mechanism (DME-unclear) DME1444 Odoribacter splanchnicus Not Available Not Available [4]
Unclear metabolic mechanism (DME-unclear) DME1447 Parabacteroides merdae Not Available Not Available [4]
⏷ Show the Full List of 9  DME(s)
References
1 Isradipine was approved by FDA. The 2020 official website of the U.S. Food and Drug Administration.
2 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
3 Isocratic high-performance liquid chromatographic method for the separation of isradipine and its main metabolites. Application to in vitro metabolization by h3A4/OR cells J Chromatogr B Biomed Sci Appl. 1997 Jun 6;693(2):359-66. doi: 10.1016/s0378-4347(97)00048-0.
4 Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019 Jun;570(7762):462-467.
5 Assay of isradipine and of its major metabolites in biological fluids by capillary gas chromatography and chemical ionization mass spectrometry J Chromatogr. 1988 Jun 24;428(1):61-9. doi: 10.1016/s0378-4347(00)83890-6.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.